STRIKING A DEAL
Technology Licensing in Cell and Gene Therapy
3:45 – 4:00pm: Registration
4:00 – 5:00pm: Program
5:00 – 6:00pm: Networking
It has been a difficult year for biotech startups seeking funding. The bear market has valuations down, making equity funding and M&A deals less appealing and harder to come by for start-ups. IPOs are virtually non-existent. However, with the pharmaceutical industry edging closer to the patent cliff for a significant number of top revenue producing drugs, the hunt to fill the pipeline for future revenue streams has top pharma companies leaving no stone unturned.
Opportunities abound with licensing deals and cell and gene therapy deals are leading the way. While licensing may currently be the most promising avenue for funding, the competition is steep, especially with more and more start-ups popping up in this field. Learn from industry veterans on what differentiates a start-up in this space seeking licensing opportunities and how to position your cell or gene therapy company for success.